Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.

Scheen, André

doi:10.1080/17425255.2017.1315102

Request a copy

Article (Scientific journals)

Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.

Scheen, André

2017 • In Expert Opinion on Drug Metabolism and Toxicology, 13 (5), p. 583-592

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/210418

DOI
10.1080/17425255.2017.1315102

PubMed
28374622

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2017 EOMT Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.pdf

Publisher postprint (1.07 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Combined therapy; DPP-4 inhibitor; SGLT2 inhibitor; fixed-dose combination; type 2 diabetes mellitus

Abstract :

[en] INTRODUCTION: Combining a dipeptidyl peptidase-4 inhibitor and a sodium-glucose cotransporter type 2 inhibitor is an attractive option to treat hyperglycaemia in type 2 diabetes. Areas covered: The saxagliptin plus dapagliflozin combination is carefully analysed, focusing on: 1) pharmacokinetic properties, 2) pharmacodynamics data, and 3) results of randomised controlled trials (dual combination versus either monotherapy, sequential therapy saxagliptin added to dapagliflozin or dapagliflozin added to saxagliptin). Expert opinion: Pharmacokinetic findings demonstrate the absence of drug-drug interaction and the bioequivalence of the FDC compared with separated tablets. Pharmacodynamic observations confirm a complementary mode of action of the two agents. Dual saxagliptin-dapagliflozin therapy is more potent than either monotherapy. It may be used as an initial combination, although this approach remains debatable and should probably be reserved in case of high glycated hemoglobin, or a stepwise strategy, according to a personalized approach. The developed saxagliptin-dapagliflozin FDC may simplify anti-hyperglycemic therapy and improve drug compliance.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.

Publication date :

2017

Journal title :

Expert Opinion on Drug Metabolism and Toxicology

ISSN :

1742-5255

eISSN :

1744-7607

Publisher :

Informa Healthcare, United Kingdom

Volume :

Issue :

Pages :

583-592

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 11 May 2017

Statistics

Number of views

54 (2 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

DeFronzo RA., Banting Lecture. From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015:a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract. 2016;22:84–113.
Barnett AH, Charbonnel B, Moses RG, et al. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:1919–1931.
Scheen AJ., A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43–62.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
Scirica BM, Braunwald E, Raz I, et al. Committee S-TS, investigators. Heart failure, saxagliptin, and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2015;132:e198.
Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 inhibitors and heart failure:class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med. 2014;16:353.
Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12:648–658.
Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501–514.
Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13:81–99.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
Scheen AJ. SGLT2 inhibitors:benefit/risk balance. Curr Diabetes Rep. 2016;16:92.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial:a critical analysis. Diabetes Metab. 2016;42:71–76.
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes:cardiovascular and kidney effects. Potential mechanisms and clinical applications. Circulation. 2016;134:752–772.
Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes:pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2014;10:647–663.
Scheen AJ. SGLT2 inhibition:efficacy and safety in type 2 diabetes treatment. Exp Opin Drug Safety. 2015;14:1879–1904.
Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus:systematic review and network meta-analysis. Diabetes Obesity Metab. 2016;18:783–794.
Guthrie RM. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgrad Medicine. 2015;127:463–479.
Sharma MD. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17:616–621.
Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38:373–375.
Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes:from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12:1407–1417.
Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab. 2009;11:527–533.
Han S, Iglay K, Davies MJ, et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens:a meta-analysis. Curr Med Res Opin. 2012;28:969–977.
Abdulsalim S, Peringadi Vayalil M, Miraj SS. New fixed dose chemical combinations:the way forward for better diabetes type II management? Expert Opin Pharmacother. 2016;17:2207–2214.
Aronson R. Single-pill combination therapy for type 2 diabetes mellitus:linagliptin plus empagliflozin. Curr Med Res Opin. 2015;31:901–911.
Woo V. Empagliflozin/linagliptin single-tablet combination:first-in-class treatment option. Int J Clin Pract. 2015;69:1427–1437.
Dhillon S, Weber J. Saxagliptin. Drugs. 2009;69:2103–2114.
Boulton DW. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clin Pharmacokinet. 2017;56:11–24.
Anderson R, Hayes J, Stephens JW. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;12:467–473.
Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405–414.
Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17–27.
Plosker GL. Dapagliflozin:a review of its use in patients with type 2 diabetes. Drugs. 2014;74:2191–2209.
Maranghi M, Carnovale A, Durante C, et al. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11:125–137.
Scheen AJ. Pharmacokinetic characteristics and clinical efficacy of a SGLT2 inhibitor plus a DPP-4 inhibitor combined therapy in type 2 diabetes. Clin Pharmacokinet. 2017;56:193–205.
Williams DM, Stephens JW. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2015;16:2373–2379.
Boulton DW, Kasichayanula S, Keung CF, et al. Simultaneous oral therapeutic and intravenous (1, 4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013;75:763–768.
Vakkalagadda B, Lubin S, Reynolds L, et al. Lack of a pharmacokinetic interaction between saxagliptin and dapagliflozin in healthy subjects:a randomized crossover study. Clin Ther. 2016;38:1890–1899.• Drug–drug interaction study demonstrating the lack of a pharmacokinetic interaction between saxagliptin and dapagliflozin in healthy subjects.
Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins):focus on drug–drug interactions. Clin Pharmacokinet. 2010;49:573–588.
Scheen AJ. Drug–drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet. 2014;53:295–304.
Vakkalagadda B, Vetter ML, Rana J, et al. Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects. Pharmacol Res Perspect. 2015;3:e00201.• Pharmacokinetic study demonstrating that saxagliptin/dapagliflozin FDC tablets are bioequivalent to coadministration of the individual components in healthy subjects under fasted conditions, without clinically meaningful effect of food intake.
Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187–1197.
Liu H, Hu Y, Li FF, et al. Blood glucagon levels predict the hemoglobin A1c response to saxagliptin in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Ther. 2016;7:743–753.
Ekholm E, Hansen L, Johnsson E, et al. Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves beta-cell function. Endocr Pract. 2017;23:258–265.
Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy:a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.•• Clinical trial showing greater improvements in glycemic control with triple therapy by the dual addition of saxagliptin and dapagliflozin than dual therapy with the addition of saxagliptin or dapagliflozin alone in T2D patients poorly controlled with metformin.
Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–2017.• Clinical trial demonstrating that triple therapy with dapagliflozin add-on to saxagliptin plus metformin improves glycemic control and is well tolerated in T2D not well controlled with saxagliptin plus metformin therapy.
Mathieu C, Herrera Mamolejo M, Gonzalez Gonzalez JG, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1134–1137.• Extension of a 24-week clinical trial confirming that the clinical benefits of triple therapy with the addition of dapagliflozin to saxagliptin plus metformin persist up to 52 weeks.
Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38:2018–2024.• Clinical trial showing that triple therapy with the addition of saxagliptin to dapagliflozin plus metformin is well tolerated and produces significant improvements in HbA1c in patients with T2D inadequately controlled with dapagliflozin plus metformin.
Matthaei S, Aggarwal N, Garcia-Hernandez P, et al. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obes Metab. 2016;18:1128–1133.• Extension of a 24-week clinical trial confirming that the clinical benefits of triple therapy with the addition of saxagliptin to dapagliflozin plus metformin persist up to 52 weeks.
Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402.
DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy in drug-naive patients with type 2 diabetes:a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator. Lancet Diabetes Endocrinol. 2013;1:208–219.
Scheen AJ. SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol. 2013;1:168–170.
Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am. 2015;99:87–106.
Scheen AJ. Precision medicine:the future in diabetes care? Diabetes Res Clin Pract. 2016;117:12–21.
Scheen AJ. SGLT2 inhibition:efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf. 2015;14:1879–1904.
Paolisso G, Monami M, Marfella R, et al. Dipeptidyl peptidase-4 inhibitors in the elderly:more benefits or risks? Adv Ther. 2012;29:218–233.
Carlson CJ, Santamarina ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf. 2016;15:1401–1412.
Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol. 2012;8:383–394.
Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40:69–76.
Fioretto P, Stefansson BV, Johnsson E, et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59:2036–2039.
Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Clin Pharmacokinet. 2015;54:691–708.
Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment:observations from the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38:696–705.
Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes:a critical reappraisal. Diabetes Metab. 2014;40:176–185.
Ghosh RK, Bandyopadhyay D, Hajra A, et al. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors:a comprehensive review of clinical and preclinical studies. Int J Cardiol. 2016;212:29–36.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk:results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.
Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories:a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
Goldenberg RM, Verma S, Perkins BA, et al. Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the Yin and Yang of glucagon? Can J Diabetes. 2017;41:6–9.
Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
Taylor SI, Blau JE, Rother KI. Perspective:SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis:a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
Garg M, Ghanim H, Kuhadiya ND, et al. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes Obes Metab. 2017 Mar 17. [Epub ahead of print]. DOI:10.1111/dom.12944
Pratley R, Eldor R, Golm G, et al. Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes mellitus inadequately controlled with metformin:the VERTIS FACTORIAL trial. Communication presented at the 52nd meeting of the European Association for the Study of Diabetes, Munich, Germany, Sept 12-6, 2016 (abstract 728).